| Regulatory status | BUNDLE |
|---|---|
| Mechanism | Dual GIP/GLP-1 + amylin analogue (two-vial bundle) |
| Form | Two lyophilized vials · 10mg + 10mg, 30mg + 10mg, 60mg + 10mg |
| CAS | Investigational (bundle of two) |
| Purity docs | Batch-matched COA available on request — ask us. |
| Ships from | Ontario, Canada |
| Intended use | Laboratory research only. Not for human consumption. |
This bundle pairs tirzepatide, the dual GIP/GLP-1, with eloralintide, the next-generation once-weekly amylin analogue — three distinct satiety pathways in a single order. In phase 2b, the combination (eloralintide 9 mg + tirzepatide 15 mg weekly, administered as separate injections) produced 23.3% mean weight loss at 48 weeks in adults with obesity and type 2 diabetes. Each bundle ships as two separate lyophilized vials — one tirzepatide at the selected strength, one eloralintide 10 mg.
Lyophilized vials: keep sealed, dry, and away from light and heat. Refrigeration at 2–8°C is the best default; −20°C for long-term storage. After reconstitution: refrigerate at 2–8°C and use promptly — no beyond-use date is validated.
The triple-pathway stack, bundled. One tirzepatide vial + one eloralintide vial.
New here? Read the beginner's guide →
$15 flat shipping Canada-wide · free over $200
The active ingredient in Ozempic and Wegovy — the original once-weekly weight-loss medicine.
GLP-1 receptor agonist
The active ingredient in Mounjaro and Zepbound — the newer, stronger once-weekly weight-loss medicine.
Dual GIP / GLP-1 receptor agonist
A once-weekly weight-loss medicine already approved in China — still experimental in Canada and the US.
Dual GLP-1 / glucagon receptor agonist
